Scott Dreyer serves as the Executive Vice President and Chief Commercial Officer at Collegium Pharmaceutical Inc., a role he has held since joining the company in 2019. In his capacity, Dreyer is responsible for overseeing the company's commercial strategy and operations, driving growth and market expansion for Collegium's portfolio of pain management products. His leadership has been instrumental in strengthening Collegium's position in the competitive pharmaceutical industry. Before joining Collegium, Dreyer amassed a wealth of experience in the pharmaceutical sector, having held key leadership positions at several prominent companies. Notably, he served as the Senior Vice President of Sales and Marketing at Insys Therapeutics, where he played a pivotal role in the successful launch and commercialization of several products. Prior to Insys, Dreyer held various sales and marketing leadership roles at companies such as Cornerstone Therapeutics, Kos Pharmaceuticals, and Knoll Pharmaceutical. His extensive background in sales, marketing, and strategic planning has been a valuable asset to Collegium, enabling the company to navigate the complex landscape of pain management therapeutics. Under Dreyer's guidance, Collegium has achieved significant milestones, including the successful launch of Xtampza ER, a novel extended-release oxycodone product designed to deter abuse. His strategic vision and execution have been crucial in expanding the company's market presence and driving revenue growth. As Collegium continues to innovate and develop new solutions for pain management, Dreyer's leadership will remain a key factor in the company's ongoing success and commitment to improving patient outcomes.